- Reuters•6 hours ago
An experimental biotech drug developed by Johnson & Johnson proved more effective at clearing moderate to severe cases of the skin condition plaque psoriasis than a placebo or Abbvie Inc's big-selling Humira, according to data from a late stage study presented on Saturday. More than 73 percent of patients who received guselkumab experienced near complete skin clearance compared with 2.9 percent those who received a placebo. In the Humira group, nearly 50 percent of patients saw near complete skin clearance.
- Bloomberg•6 hours ago
Johnson & Johnson’s experimental drug for psoriasis hit its main goals and outperformed a rival in a final-stage study, positioning the company to expand its arsenal of immune-disease treatments.
- Reuters•7 hours ago
Novartis's psoriasis drug Cosentyx showed long-term efficacy in keeping patients' skin clear, the Swiss drugmaker said on Saturday, citing a study it hopes will ultimately help the company to win business from rival medicines made by Amgen and Johnson & Johnson . More than 66 percent of Cosentyx patients achieved "clear or almost clear" skin after four years, Novartis said, comparable with the 68.5 percent who hit that milestone after one year. A durable response is important, since older biotech drugs for plaque psoriasis, known as anti-TNFs, can lose their effectiveness over time.
Johnson & Johnson (JNJ)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||117.85 x 400|
|Ask||118.29 x 500|
|Day's Range||117.39 - 118.62|
|52wk Range||92.58 - 126.07|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||22.01|
|Avg Vol (3m)||6,259,060|
|Dividend & Yield||3.20 (2.73%)|